AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 3, 2024

Navigating regulatory affairs in the biopharma industry requires a skilled talent pool, according to Benjamin James, HR Leader, Asia-Pacific, Cytiva Lifesciences – a global life sciences (biopharma) company. in 2021 to 5.60 […]

HR 183

HR Life Science Clinical Trials Clinical Trials 183

XTalks

MAY 31, 2024

Mercer and Marsh recently released its “ 2024 People Risk Report ,” which highlights critical areas for healthcare HR professionals. Let’s delve into why these points are crucial for healthcare HR professionals, ensuring resilient and effective management of workforces. The collaboration between HR and risk professionals is vital.

HR 52

HR Compliance Containment Development 52

pharmaphorum

MARCH 26, 2025

LEAP HR: Life Sciences East Sara.Scarpinati Wed, 26/03/2025 - 09:00 Bookmark this

HR 52

HR Life Science 52

Pharmaceutical Technology

SEPTEMBER 13, 2022

Hormone receptor-positive/human epidermal growth factor negative (HR+/HER2-) breast cancer accounts for approximately 70% of all breast cancers, with close to 40,000 new cases diagnosed each year worldwide. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

HR 162

HR Marketing Hormones FDA Approval 162

Pharmaceutical Technology

JUNE 9, 2023

The subunit antigen in the vaccine has been based on the structure of the targeting S-RBD and HR proteins of the XBB and BA.5 WestVac Biopharma and its subsidiary WestVac Biopharma (Guangzhou) constructed the vector for the coviccine vaccine using the fast response of the insect cell expression platform. 5 subvariants.

Vaccination 269

Vaccination Vaccine Protein HR 269

BioSpace

MARCH 26, 2024

BioSpace spoke to HR leaders about how they have been supporting companies navigating a challenging economy while meeting the needs of the workforces they support.

HR 59

HR Marketing 59

Medical Xpress

DECEMBER 6, 2022

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 (..)

HR 70

HR Genome Genomics Hormones 70

Pharmaceutical Technology

NOVEMBER 17, 2023

Truqap is approved in combination with Faslodex for HR-positive/HER2-negative breast cancer patients in the US.

FDA Approval 130

FDA Approval HR 130

Pharmaceutical Technology

JULY 28, 2023

Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.

HR 130

HR Drugs 130

Medical Xpress

JANUARY 31, 2025

Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

HR 49

HR FDA Approval Hormones Drugs 49

BioSpace

MAY 5, 2021

We interviewed Krissy Fuller, a human resources consultant, to learn more about the issue of mandated vaccines from an HR perspective and shared her predictions on what changes she thinks will last after the pandemic.

HR 56

HR Vaccination Vaccine 56

BioTech 365

NOVEMBER 16, 2020

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services CALGARY, Alberta–(BUSINESS WIRE)–#albertadentist–With businesses everywhere struggling to keep their doors … Continue reading (..)

HR 40

HR 40

XTalks

JANUARY 30, 2025

Novartis has spent three decades advancing breast cancer treatments, focusing on hormone receptor-positive (HR+), HER2-negative breast cancer, the most common subtype. Last year, the FDA approved Kisqali (ribociclib) to reduce the risk of recurrence in HR+/HER2- early breast cancer.

HR 65

HR Hormones FDA Approval Clinical Trials 65

World of DTC Marketing

JANUARY 14, 2022

One of the people I work with has more than 20 years of experience as an HR VP. Yet, when she was contacted about taking over a small companies HR department, she declined because the hiring process consisted of too many interviews over too long a period. Stories about hiring processes within pharma are more like nightmares.

HR 277

HR Production Pharma Companies Marketing 277

BioTech 365

SEPTEMBER 19, 2021

Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer With the MONALEESA-2 final analysis, only … Continue reading →

HR 52

HR 52

Pharmaceutical Commerce

NOVEMBER 17, 2023

The FDA also approved a companion diagnostic test to detect the PIK3CA, AKT1, and PTEN alterations as part of the approval for AstraZeneca’s capivasertib (Truqap) plus fulvestrant (Faslodex) for HR-positive, HER2-negative locally advanced or metastatic breast cancer.

HR 52

HR 52

Pharmaceutical Technology

JUNE 2, 2023

Data from Novartis ’ Phase III NATALEE trial show that adding Kisqali to endocrine therapy lowered the risk of cancer recurrence by 25% in patients with hormone receptor-positive (HR+)/HER2- early-stage breast cancer (EBC).

HR 130

HR Hormones Trials Drugs 130

Scienmag

JUNE 30, 2021

Credit: NTU Singapore Nanyang Technological University, Singapore (NTU Singapore) is collaborating with the Institute for Human Resource Professionals (IHRP) to launch two new MiniMasters™ programmes to develop talent in human resources (HR).

HR 89

HR Development 89

Pharmaceutical Technology

MARCH 6, 2023

Verzenio along with endocrine therapy (ET) has received approval as an adjuvant treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) adult patients who are at a high recurrence risk.

FDA Approval 130

FDA Approval HR Hormones Clinical Trials 130

pharmaphorum

NOVEMBER 27, 2024

Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours.

HR 98

HR Drugs 98

Pharmaceutical Technology

JUNE 4, 2023

in the placebo arm (hazard ratio [HR]: 0.58). months in the placebo arm (HR: 0.73). At a median duration of follow-up of 25.2 months, the two-year event-free survival (EFS) was 62.4% in the Keytruda arm, versus 40.6% The median EFS was not reached in the Keytruda arm, and was 17 months in the placebo arm.

HR 189

HR FDA Approval Trials Marketing 189

BioTech 365

SEPTEMBER 28, 2021

This HR+/HER2-VE Breast … Continue reading →

HR 40

HR Clinical Trials Clinical Trials Trials 40

Scienmag

DECEMBER 9, 2021

Credit: SWOG/The Hope Foundation In an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer, a standard measure of gene expression known as the sensitivity-to-endocrine-therapy (SET2,3) index was found to have prognostic value that complemented the known prognostic value of the 21-gene breast recurrence score.

HR 80

HR Gene Expression Hormones Gene 80

XTalks

JANUARY 21, 2025

The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca.

Antibody 105

Antibody FDA Approval HR Trials 105

The Pharma Data

SEPTEMBER 21, 2020

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients whose tumours are PIK3CA positive. months compared to 14.8

HR 52

HR Hormones Trials 52

BioTech 365

SEPTEMBER 5, 2020

| Añadir a lista de seguimiento Biotech365 : ^^BIORAD 7500502 Signal Importación Módulo Hr – Nuevo BioMarketplace You want to propose your products or a Biotech … Continue reading →

HR 40

HR Production 40

Scienmag

SEPTEMBER 20, 2020

Data from latest research presented at the ESMO Virtual Congress 2020 Lugano, Switzerland, 20 September 2020 – Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to (..)

HR 45

HR Hormones Drugs Research 45

BioPharma Reporter

SEPTEMBER 19, 2024

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) stage two or three early breast cancer, who are at high risk of cancer recurrence.

FDA Approval 93

FDA Approval HR Hormones Marketing 93

ACRP blog

NOVEMBER 13, 2023

There’s no doubt that organizations are struggling with the acquisition and retention of drug research and development talent, and the longer this goes on, the clearer it becomes that there are forces at work that no amount of wishful thinking about “Employee Value Propositions” by human resources (HR) functionaries can address.

HR 52

HR Medicine Development Drugs 52

Pharmaceutical Technology

SEPTEMBER 26, 2022

The 'life-extending' drug combination is recommended for usage in adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer who have previously received hormone therapy. In addition to palbociclib, NICE has granted approval for 15 other therapies for breast cancer since 2018.

HR 130

HR Drugs Hormones Medicine 130

BioSpace

SEPTEMBER 21, 2023

The companies’ antibody-drug conjugate improved progression-free survival with a “trend in improvement” for overall survival in patients with HR-positive, HER2-low or negative breast cancer.

HR 91

HR Antibody Drugs 91

BioSpace

NOVEMBER 16, 2023

The company's Truqap, in combination with its endocrine therapy Faslodex, has been approved by the regulator for adult patients with advanced HR-positive breast cancer with specific biomarker alterations.

FDA Approval 90

FDA Approval HR Regulation 90

BioTech 365

APRIL 15, 2021

BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada BioTalent Canada cements status as Canada’s voice for biotechnology HR with spot on list of Best Workplaces in Canada OTTAWA, Ontario–(BUSINESS … Continue reading →

HR 40

HR 40

BioTech 365

MARCH 26, 2021

Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Phase 2b VITAL study of Gemogenovatucel-T (Vigil™) immunotherapy demonstrates clinical benefit in homologous recombination (HR) proficient ovarian cancer Results from pre-planned subgroup (..)

HR 40

HR 40

Pharmaceutical Technology

JULY 25, 2022

AstraZeneca noted that the sBLA is based on findings from the randomised, open-label Phase III DESTINY-Breast04 clinical trial of Enhertu in priorly treated subjects with HER2-low metastatic breast cancer with hormone receptor (HR)-positive or HR-negative disease.

HR 130

HR Hormones Clinical Trials Clinical Trials 130

Worldwide Clinical Trials

NOVEMBER 13, 2024

By; Brooke Kaplan, Director, People Partner- HR Compliance & Human Capital Initiatives In April 2007, at 19 years old, I was a sophomore at the University of Maryland. I had always been relatively healthy, exercised recreationally, and worked part-time at the campus gym.

Insulin 162

Insulin Doctor Doctors Clinical Trials 162

Scienmag

MARCH 2, 2022

In 2020 a team led by European Southern Observatory (ESO) astronomers reported the closest black hole to Earth, located just 1000 light-years away in the HR 6819 system. But the results of their study were contested by other researchers, including by an international team based at KU Leuven, Belgium.

Containment 95

Containment HR Research 95